the overall risk of hypercholesterolemia in men and women is lower at a young age. During “menopause, total cholesterol and low-fat lipoproteins (LDL)” increases separately by 10 and 14% and “lipoprotein (a) from 4 to 8%”, although the cholesterol of “high-fat lipoproteins (HDL)” remains unchanged. Therefore, it may be necessary to re-estimate the “lipid profile after menopause” if marginal features are found before menopause. Over 65 means that on the contrary, “LDL cholesterol” is higher in men and women. In all age groups, the “HDL cholesterol” level in women is between 0.26 and 0.36 mmol / l; However, according to the Framingham study, low HDL cholesterol levels are associated with a higher risk of “coronary heart disease” in women than in men (Schenck-Gustafsson and Fridner, 2017).
Despite the fact that women have frequently been asked about many statin eliminations, it is currently believed that with optional suppression, the decrease in LDL in women causes an equally low “CHD mortality” compared to men. On the other hand, the effects of statin therapy on women in the event of a significant drop out of school are still questionable. However, notification is required because women in the concentrated age groups have so far been less at risk. A large ongoing Japanese review has shown that it is far from the statin needed to fight women with moderately high cholesterol over 55 years of age (Schenck-Gustafsson and Fridner, 2017). The age contrast of coronary artery disease between men and women was presented in the introductory “JUPITER”, where practically identical benefits were found in the need to avoid statins in “healthy men ≥50 years old” and in women “≥60 years” with normal “LDL levels”, however high CRP values